GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genscript Biotech Corp (OTCPK:GNNSF) » Definitions » Retained Earnings

GNNSF (Genscript Biotech) Retained Earnings : $-787 Mil (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Genscript Biotech Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Genscript Biotech's retained earnings for the quarter that ended in Jun. 2024 was $-787 Mil.

Genscript Biotech's quarterly retained earnings declined from Jun. 2023 ($-610 Mil) to Dec. 2023 ($-612 Mil) and declined from Dec. 2023 ($-612 Mil) to Jun. 2024 ($-787 Mil).

Genscript Biotech's annual retained earnings declined from Dec. 2021 ($-289 Mil) to Dec. 2022 ($-516 Mil) and declined from Dec. 2022 ($-516 Mil) to Dec. 2023 ($-612 Mil).


Genscript Biotech Retained Earnings Historical Data

The historical data trend for Genscript Biotech's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genscript Biotech Retained Earnings Chart

Genscript Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -289.19 -516.04 -611.52

Genscript Biotech Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -516.04 -609.62 -611.52 -786.63

Genscript Biotech Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Genscript Biotech  (OTCPK:GNNSF) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Genscript Biotech Business Description

Traded in Other Exchanges
Address
No. 28, Yongxi Road, Jiangning Science Park, Jiangsu Province, Nanjing, CHN, 211100
Genscript Biotech Corp is a China-based provider of life science research services and products. it is known for its gene synthesis capabilities, a widely used service by academics, biotech companies, and pharmaceutical companies around the world. Its business lines include life science research services and products, biologics development services under its ProBio brand, and industrial enzymes under its Bestzyme brand. Finally, The company estimates that over two-thirds of GenScript valuation is from its ownership stake in Legend.